European Archives - Page 708 of 1392 - European Medical Journal

Channelling the Myotonia Diagnosis: ICNMD Symposium Presentations

Watch full presentations given by Prof. Dr Kristl Claeys, Dr Guillaume Bassez and Prof. John Vissing at the Lupin-sponsored symposium at the 17th International Congress on Neuromuscular Diseases, in July 2022, in Brussels, Belgium.

Overcoming COVID-19 Misinformation: Lessons Learned at the Epicentre of the Outbreak in the USA

THE COVID-19 pandemic has highlighted the dire need to foster increased public confidence in mitigation and prevention strategies through more and better health literacy.

Revealing the true value of medical affairs

Why is the purpose and value of medical affairs sometimes poorly understood by the wider pharma organisation, and what can be done?

Meet GOLD's new catalyst – GSK's John Wahba

Helena and Isabel share an interview with GOLD’s new catalyst John Wahba, Medical Head of the Global Digital Hub, GS

Davidek Herron on the future of pharma

In his second column, Davidek Herron, Global Head of Digital, Roche, considers this year’s successes and challenges and looks ahead to 2023.

Çetin Erol

Interview: Çetin Erol

We are honoured to share our EMJ Cardiology 2022 in review interview with Çetin Erol, Cardiologist at İbn-i Sina Hospital, Faculty of…

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Chaired by Prof. Andrea Necchi, this symposium presented by Prof. Rouprêt and Prof. Retz explores the treatment landscape for muscle-invasive urothelial carcinoma, as well as their perspectives on future treatment landscape.

Interview: Antonio Rossi

We are honoured to share our EMJ Respiratory interview with Antonio Rossi, Senior Medical Director, Oncology Center of Excellence…

EMJ Oncology 10 [Supplement 12] 2022

This article covers a symposium that took place on 10th September 2022 as part of the European Society for Medical Oncology (ESMO) annual congress held in Paris, France, from 9th–13th September 2022.

Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine

Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.